Portfolio

Drug manufacturer AbbVie (NYSE:ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions.
With profit margins of at least 17% in each of the past five years and annual revenue rising from $20 billion in 2014 to $33.3 billion in 2019, AbbVie's business was already looking strong.
But the healthcare company became an even better investment when it acquired Allergan, which makes Botox, in a massive $63 billion deal. AbbVie announced the closing of the acquisition, which greatly expands its portfolio of products, on May 8 2020.

Dividend

A stronger and more diverse business model helps make prospects for its dividend even better. And that's key for a Dividend Aristocrat that's known for growing its payments over the years. Since spinning off from Abbott Labs in 2013, AbbVie has increased its dividend payments by 195%.
Today, it pays investors a quarterly dividend of $1.18, for a yield of 5% annually. An $8,000 investment in AbbVie would bring investors $400 for the year, or $100 every three months. Its quarterly payments come every February, May, August, and November.
Year to date, shares of AbbVie are up 6%, right in line with the S&P 500's returns.